Company Filing History:
1 out of 22 
1 out of 321 
Years Active: 2020
Title: Innovations of Chan Mi Chun in Chronic Obstructive Pulmonary Disease Treatment.
Introduction
Chan Mi Chun is an innovative inventor based in Daejeon, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of chronic obstructive pulmonary disease (COPD). His work focuses on developing effective compositions that can alleviate the symptoms of this debilitating condition.
Latest Patents
Chan Mi Chun holds a patent for a composition containing a monoacetyldiglyceride compound as an active ingredient for preventing or treating chronic obstructive pulmonary disease. The invention relates to a pharmaceutical composition that not only addresses COPD but also serves as a functional health food composition. The monoacetyldiacylglycerol compound inhibits IL-4 expression in EL-4 cells and reduces the infiltration of inflammatory cells into the bronchial tubes in animal models. This compound demonstrates an excellent ability to inhibit the expression of CXCL-1, TNF-α, and MIP-2, thus overcoming the side effects associated with currently used therapeutic agents for COPD. The invention is notable for its lack of toxicity and superior therapeutic effects, making it a promising option for patients suffering from this disease.
Career Highlights
Throughout his career, Chan Mi Chun has worked with notable organizations such as Enzychem Lifesciences Corporation and the Korea Research Institute of Bioscience and Biotechnology. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Chan Mi Chun has collaborated with esteemed colleagues, including Sei-Ryang Oh and Kyung Seop Ahn. These partnerships have facilitated the advancement of his research and the development of innovative solutions for chronic obstructive pulmonary disease.
Conclusion
Chan Mi Chun's contributions to the field of pharmaceuticals, particularly in the treatment of chronic obstructive pulmonary disease, highlight his innovative spirit and dedication to improving patient outcomes. His patented compositions represent a significant advancement in therapeutic options for COPD, showcasing the potential for future developments in this area.